pharMETHOD - Event Registration

Hormonal Aspects of Breast Cancer Live Web-Based Lecture Series

Please register below for HABC Live Web-Based Lecture Series

Please be aware that we will use your personally identifiable information to contact you about your participation in the program. This information is governed by AstraZeneca’s Privacy Policy.

AstraZeneca respects your personal information. The information you provide may be used to send you materials and to develop products, services, and programs. AstraZeneca, or third parties working on our behalf, will not sell or rent your personal information. Please visit www.azprivacystatement.com to review our Privacy Statement.

By submitting this information, you agree to these conditions.

Registration for Live Program

Early Breast Cancer Topics:
Speaker	Topic	Date	Time		Select

Metastatic Breast Cancer Topics:
Speaker	Topic	Date	Time		Select

* First/Last Name, Degree :

* Specialty:

Affiliation:

* Country:

* Address 1:

Address 2:

* City, State and Zip Code:

* Phone Number:

Fax Number:

Cell Phone Number:

* E-mail Address:

* Verify E-mail Address:

Yes, I would like to enroll to receive e-mail invitations for upcoming events in the Hormonal Aspects of Breast Cancer series

Yes, I would like to receive information in the future about breast cancer and related AstraZeneca products and services

* denotes required field

Important Information About ARIMIDEX^® (anastrozole) Tablets

ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with estrogen receptor-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX.

Important Safety Information About ARIMIDEX

ARIMIDEX is only for postmenopausal women. ARIMIDEX can cause fetal harm when administered to a pregnant woman. Before starting treatment with ARIMIDEX, pregnancy must be excluded (see CONTRAINDICATIONS section of full Prescribing Information).

In women with preexisting ischemic heart disease 465/6186 (7.5%), an increased incidence of ischemic cardiovascular events occurred with ARIMIDEX (17%) vs tamoxifen (10%). In this patient population, angina pectoris was reported in 25/216 (11.6%) vs 13/249 (5.2%) and myocardial infarction was reported in 2/216 (0.9%) vs 8/249 (3.2%) patients receiving ARIMIDEX and tamoxifen, respectively.

Compared to baseline, ARIMIDEX showed a mean decrease in both lumbar spine and total hip bone mineral density. Tamoxifen showed a mean increase in these measurements. Nine percent of patients receiving ARIMIDEX had an elevated serum cholesterol vs 3.5% of patients receiving tamoxifen.

Common side effects seen with ARIMIDEX vs tamoxifen in the early breast cancer trial after 5 years of treatment include hot flashes (36% vs 41%), joint disorders (including arthritis, arthrosis, arthralgia) (36% vs 29%), asthenia (19% vs 18%), mood disturbances (19% vs 18%), pain (17% vs 16%), pharyngitis (14% vs 14%), nausea and vomiting (13% vs 12%), rash (11% vs 13%), depression (13% vs 12%), hypertension (13% vs 11%), osteoporosis (11% vs 7%), peripheral edema (10% vs 11%), lymphedema (10% vs 11%), back pain (10% vs 10%), insomnia (10% vs 9%), and headache (10% vs 8%). Fractures, including fractures of the spine, hip, and wrist, occurred more often with ARIMIDEX vs tamoxifen (10% vs 7%).

In the advanced breast cancer studies, the most common (occurring with an incidence of >10%) side effects occurring in women taking ARIMIDEX included hot flashes, nausea, asthenia, pain, headache, back pain, bone pain, increased cough, dyspnea, pharyngitis, and peripheral edema. Joint pain/stiffness has been reported in association with the use of ARIMIDEX.

Clinical and pharmacokinetic results suggest that tamoxifen should not be administered with ARIMIDEX. Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.

View ARIMIDEX full Prescribing Information

Important Information About FASLODEX^®(fulvestrant) Injection

FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Important Safety Information About FASLODEX

FASLODEX is only for postmenopausal women. FASLODEX can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised not to become pregnant while receiving FASLODEX. (See CONTRAINDICATIONS and WARNINGS sections of full Prescribing Information.)

Because FASLODEX is administered intramuscularly, it should not be used in patients with bleeding diatheses, thrombocytopenia, or in patients on anticoagulants.

In clinical trials, the most commonly reported adverse events seen with FASLODEX, regardless of the investigator's assessment of causality, were gastrointestinal symptoms (nausea 26.0%, vomiting 13.0%, constipation 12.5%, diarrhea 12.3%, abdominal pain 11.8%), headache (15.4%), back pain (14.4%), hot flushes (17.7%), and pharyngitis (16.1%). Injection site reactions with mild, transient pain and inflammation were reported in 7% of patients (1% of treatments) given single 5 mL injection and 27% of patients (4.6% of treatments) given 2 x 2.5 mL injections of FASLODEX.

View FASLODEX full Prescribing Information